Utility of Two PANSS 5-Factor Models for Assessing Psychosocial Outcomes in Clinical Programs for Persons with Schizophrenia

Table 3

Estimated means and standard errors for RFS, SAS, and CSQ measures by medication group and time period.

	Baseline mean; (SE) ± SD	3 months mean; (SE) ± SD	6 months mean; (SE) ± SD	9 months mean; (SE) ± SD	12 months mean; (SE) ± SD
OLANZAPINE; (𝑁=30)
RFS total; SAS-SMI total; CSQ-8 total; Adherence; Compliance	2.31 (0.21); 67.26 (3.72); 21.23 (1.19); 36.43±36.27; 3.57±0.79	3.33 (0.24); 79.36 (4.50); 21.30 (1.48); 70.86±26.84; 3.56±0.65	3.50 (0.30); 61.60 (5.79); 24.71 (2.14); 87.43±14.27; 3.53±0.66	3.51 (0.27); 72.09 (4.95); 22.97 (1.79); 83.52±22.52; 3.62±0.59	3.54 (0.26); 71.25 (4.69); 23.97 (1.66); 81.16±24.27; 3.68±0.58
RISPERIDONE; (𝑁=36)
RFS total; SAS-SMI total; CSQ-8 total; Adherence; Compliance	2.17 (0.19); 59.45 (3.40); 21.20 (1.10); 44.93±39.04; 3.75±0.58	2.66 (0.24); 64.53 (4.46); 25.65 (1.49); 71.69±25.70; 3.43±0.75	2.67 (0.25); 60.65 (4.82); 24.48 (1.81); 71.68±28.15; 3.25±0.88	2.61 (0.25); 63.10 (4.64); 21.70 (1.57); 80.48±18.72; 3.16±0.79	2.52 (0.25); 59.40 (4.64); 19.90 (1.83); 69.42±25.78; 3.28±0.71
CONVENTIONAL; (𝑁=42)
RFS total; SAS-SMI total; CSQ-8 total; Adherence; Compliance	2.48 (0.18); 67.64 (3.14); 22.24 (1.02); 75.28±27.53; 2.65±0.83	2.75 (0.24); 60.63 (4.33); 25.93 (1.63); 72.24±27.89; 3.21±0.85	2.98 (0.29); 65.66 (5.61); 25.55 (2.30); 77.68±28.04; 3.32±0.79	3.21 (0.27); 78.73 (5.13); 27.08 (1.74); 72.90±28.85; 3.23±0.84	3.11 (0.27); 77.43 (5.08); 25.93 (1.83); 77.28±27.11; 3.28±0.84